Thale Kristin Olsen

Thale Kristin Olsen

Auto-generated profile, based on publicly available information

Thale Kristin Olsen

Department of Immunology, Genetics and Pathology Uppsala University Uppsala Sweden

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
ABAnna Borgenvik
Anna Borgenvik
KHKarl O Holmberg
Karl O Holmberg
SBSara Bolin
Sara Bolin
MZMiao Zhao
Miao Zhao
VSVasil Savov
Vasil Savov
FSFredrik Swartling
Fredrik Swartling
Relapse is the leading cause of death in patients with medulloblastoma, the most common malignant pediatric brain tumor. A better understanding of the mechanisms underlying recurrence could lead to more effective therapies for targeting tumor relapses. Here, we observed that SOX9, a transcription factor and stem cell/glial fate marker, is limited to rare, quiescent cells in high-risk medulloblastoma with MYC amplification. In paired primary-recurrent patient samples, SOX9-positive cells accumulated in medulloblastoma relapses. SOX9 expression anti-correlated with MYC expression in murine and human medulloblastoma cells. However, SOX9-positive cells were plastic and could give rise to a MYC high state. To follow relapse at the single-cell level, an inducible dual Tet model of medulloblastoma was developed, in which MYC expression was redirected in vivo from treatment-sensitive bulk cells to dormant SOX9-positive cells using doxycycline treatment. SOX9 was essential for relapse initiation and depended on suppression of MYC activity to promote therapy resistance, epithelial–mesenchymal transition, and immune escape. p53 and DNA repair pathways were downregulated in recurrent tumors, whereas MGMT was upregulated. Recurrent tumor cells were found to be sensitive to treatment with an MGMT inhibitor and doxorubicin. These findings suggest that recurrence-specific targeting coupled with DNA repair inhibition comprises a potential therapeutic strategy in patients affected by medulloblastoma relapse. Significance: SOX9 facilitates therapy escape and recurrence in medulloblastoma via temporal inhibition of MYC/MYCN genes, revealing a strategy to specifically target SOX9-positive cells to prevent tumor relapse.

14 January 2025 in Cancer Research
Verified
Journal Article
Open access
PDF file
BEBethel Tesfai Embaie
Bethel Tesfai Embaie
HSHirak Sarkar
Hirak Sarkar
AAAdele Mirna. Alchahin
Adele Mirna. Alchahin
JOJörg Otte
Jörg Otte
TOThale Kristin. Olsen
Thale Kristin. Olsen
NBNinib Baryawno
Ninib Baryawno
Transgenic mice and organoid models, such as three-dimensional tumoroid cultures, have emerged as powerful tools for investigating cancer development and targeted therapies. Yet, the extent to which these preclinical models recapitulate the cellular identity of heterogeneous malignancies, like neuroblastoma, remains to be validated. In this study, we characterized the transcriptional landscape of TH-MYCN tumors by single-cell RNA sequencing and developed ex vivo tumoroids. Integrated analysis with murine fetal adrenal samples confirmed that both TH-MYCN tumors and tumoroids closely mirror the cellular profiles of normal embryonic sympathoblasts and chromaffin cells. Comprehensive comparison between tumors from patients with neuroblastoma and TH-MYCN mice demonstrated similarities in adrenergic tumor cell composition. Ex vivo tumoroid cultures displayed histologic resemblance and shared transcriptional profiles with the originating TH-MYCN tumors and human neuroblastoma tumors. Importantly, subpopulations within tumoroids exhibited gene expression associated with poor survival of patients with neuroblastoma. Notably, recurrent observations of a low-proliferative chromaffin phenotype connected to the highly proliferative sympathetic phenotype suggested that pushing sympathoblasts into a chromaffin-like state may offer an interesting therapeutic strategy for neuroblastoma. Together, this study not only deepens our understanding of a widely used transgenic mouse neuroblastoma model but also introduces an ex vivo model that maintains critical adrenergic cell state identity, thereby enhancing its translational potential for neuroblastoma research. Significance: Transgenic mouse models and ex vivo tumoroids, characterized through single-cell RNA sequencing, faithfully recapitulate neuroblastoma cellular identity, offering a useful platform for investigating potential therapeutic strategies.

2 May 2025 in Cancer Letters
Verified
Journal Article
Open access
JMJelena Milosevic
Jelena Milosevic
SFSusanne Fransson
Susanne Fransson
JSJohanna Svensson
Johanna Svensson
JOJörg Otte
Jörg Otte
TOThale K. Olsen
Thale K. Olsen
JJJohn Inge Johnsen
John Inge Johnsen
Segmental gain of chromosome 17q is the most common genetic aberration in high-risk neuroblastoma, but its role in disease progression is poorly understood. This study aims to address the contribution of 17q gain to neuroblastoma malignancy. We analyzed the genetic and transcriptional landscape of 417 neuroblastoma patients across various risk groups and clinical stages using multi-omic approaches. Single-cell RNA/DNA sequencing and SNP arrays were combined to characterize genomic aberrations, while evolutionary trajectories were mapped to explore the accumulation of genetic changes in patients with neuroblastoma. Additionally, DNA and RNA sequencing were used to assess mutational burden and gene expression patterns. Our findings suggest that chromosome 17 gain is an early genetic event acquired during neuroblastoma development, correlating with the accumulation of additional chromosomal aberrations and poor prognosis. Increased segmental gains of chromosome 17q were observed during clonal evolution, relapse disease and metastasis. We identified PPM1D, a p53-inducible Ser/Thr phosphatase located on chr17q22.3, as a key player activated by segmental 17q-gain, gene-fusion, or gain-of-function somatic and germline mutations, further promoting neuroblastoma development/progression. Gain of chromosome 17 is an early driver of genetic instability in neuroblastoma, with PPM1D emerging as a potential candidate gene implicated in high-risk disease progression.

17 June 2026
Verified
Other
Open access
BEBethel Tesfai Embaie
Bethel Tesfai Embaie
HSHirak Sarkar
Hirak Sarkar
AAAdele M. Alchahin
Adele M. Alchahin
JOJörg Otte
Jörg Otte
TOThale Kristin Olsen
Thale Kristin Olsen
NBNinib Baryawno
Ninib Baryawno
Figure S8. Homozygous and hemizygous ex vivo tumoroid cultures. Related to Figure 4.

17 June 2026
Verified
Other
Open access
PDF file
BEBethel Tesfai Embaie
Bethel Tesfai Embaie
HSHirak Sarkar
Hirak Sarkar
AAAdele M. Alchahin
Adele M. Alchahin
JOJörg Otte
Jörg Otte
TOThale Kristin Olsen
Thale Kristin Olsen
NBNinib Baryawno
Ninib Baryawno
Figure S14. Survival probability for neuroblastoma patients MYCN amplified tumors with tumoroid enriched gene expression programs. Related to Figure 5.

17 June 2026
Verified
Other
Open access
BEBethel Tesfai Embaie
Bethel Tesfai Embaie
HSHirak Sarkar
Hirak Sarkar
AAAdele M. Alchahin
Adele M. Alchahin
JOJörg Otte
Jörg Otte
TOThale Kristin Olsen
Thale Kristin Olsen
NBNinib Baryawno
Ninib Baryawno
Figure S4. Tumor hallmark gene expression patterns in human and mouse tumors.